A DNA gap became a transcription switch activated by its target sequence
Researchers developed programmable base-gap switches that stop RNA polymerase until matching target DNA fills the engineered gap. Nature Sensors and Scienmag report that the system can distinguish single-nucleotide differences and produce different protein outputs for pathogen and cancer-associated DNA variants. Laboratory validation with some clinical samples demonstrates the approach’s sensitivity; it is not yet an approved diagnostic test or a routine clinical tool.
Science··Midday
A gap holds transcription in check
Nature Sensors and Scienmag report the same biosensor study linking an engineered gap in DNA to the presence of a target sequence. Without the target, RNA polymerase cannot cross the gap in the template strand and protein production stays off. When complementary target DNA fills the gap and permits ligation, transcription begins. The researchers attached these base-gap switches to different genes, turning a DNA input into a fluorescent-protein or enzyme output and combining recognition with output generation in one programmable circuit.[1], [2]
Two pathogens separated in one vessel
The team first cross-tested seven switches against their targets; off-target activity was low except for one pair intentionally designed with high sequence similarity. It then ran two circuits in one vessel for sequences from Neisseria gonorrhoeae and Chlamydia trachomatis. Each target induced its assigned enzyme, and both were detected down to 12 copies per microliter without crossed outputs. DNA underwent recombinase polymerase amplification to reach that threshold, so the result does not amount to a direct amplification-free point-of-care test.[1], [2]
Clinical samples, not a clinical test
A circuit for Trichomonas vaginalis was tested on DNA extracted from clinical specimens and compared with the laboratory’s quantitative polymerase chain reaction (PCR) result; the researchers also distinguished the EGFR T790M variant at fractions of 0.5 percent or more in synthetic DNA mixtures. The study used a small clinical sample set, the EGFR test used synthetic sequences, and single-nucleotide discrimination requires placing the variant beside the ligation junction. Three authors are inventors on a related patent application. The findings demonstrate programmability, while diagnostic accuracy, clinical benefit and regulatory approval remain unestablished.[1], [2]
